Last reviewed · How we verify
NCT06597045: BIOCAPRI
BIOMARKER and IMAGING CHARACTERISATION of INFLAMMATORY ATHEROMA in PATIENTS RECEIVING IMMUNOTHERAPY and ANGIOGENESIS INHIBITORS
trial testing PET/CT with 18-FDG in Cancer in 60 participants. Participants enrolled and being followed up; not accepting new ones.
14 October 2024
Quick facts
| Lead sponsor | NHS Greater Glasgow and Clyde |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 30 August 2022 |
| Primary completion | 14 October 2024 |
| Estimated completion | 20 November 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- PET/CT with 18-FDG — full drug profile →
Conditions studied
- Cancer — all drugs for Cancer →
- Cardiotoxicity — all drugs for Cardiotoxicity →
- Atherosclerotic Disease — all drugs for Atherosclerotic Disease →
Sponsor
NHS Greater Glasgow and Clyde — full company profile →
Who can join
18 and older, any sex, with Cancer or Cardiotoxicity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The advent of immunotherapy (immune checkpoint inhibitors \[ICI\]) has been an extremely important advancement for cancer treatment in recent decades. The anti-cancer effects of these agents is profound and can lead to radiological \'disappearance\' of the primary cancer and metastatic deposits. ICI are now commonly used in the treatment of multiple cancers including melanoma, kidney cancer, liver cancer and lung cancer. ICI can be used on their own or in combination with other agents such as vascular endothelial growth factor inhibitors (VEGFi) which is first line treatment for many patients. However, it has become clear that these drugs have cardiovascular side effects including high blood pressure and a reduction in the heart muscle pumping function. It is also increasingly recognised that ICIs may have a toxic effect on blood vessels resulting in an increased risk of heart attack or stroke. These side effects can have a significant impact on patients\' health and can lead to withdrawal of important cancer treatment. The mechanisms by which these side effects occur are unclear and have not been well described to date. The aim of this study is to examine the effect of ICI and VEGFi, both alone and in combination, on blood vessels and to understand their effects on blood markers and heart function. This study is observational and will not require any modification of cancer therapy. This study will aim to recruit patients diagnosed with cancer who are already planned to receive ICI or VEGFi alone or in combination at the Beatson West of Scotland Oncology Centre. Patients will undergo a vascular PET-CT scan before and 6 months after starting treatment. In addition patients will undergo echocardiography and tests of the function of the small blood vessels in the fingertips with a special machine (EndoPat). Blood and urine samples will also be collected.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06597045
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PET/CT with 18-FDG
Trials testing the same drug.
- NCT07306975 — Comparative Analysis of SUV Measurements Using Different Correction Methods in Oncological PET/CT Imaging. · not yet recruiting
- NCT07163806 — Volumetric Parameter of 18F-FDG PET/CT in Characterizing Thyroid Incidentalomas · not yet recruiting
- NCT07010484 — Using Novel Imaging to Rethink Diagnostic and Treatment Strategies for Polymyalgia Rheumatica · recruiting
- NCT06629207 — Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder · NA · recruiting
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other NHS Greater Glasgow and Clyde trials
Trials by the same sponsor.
- NCT07403890 — Rewiring the Brain-Immune Axis for Chronic Pain Using Transcranial Magnetic Stimulation in Psoriatic Arthritis · NA · not yet recruiting
- NCT07372508 — Glasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions · NA · not yet recruiting
- NCT07391280 — Strategy for EArly Recognition of Cancer, COPD & Heart Failure in the Emergency Department · NA · not yet recruiting
- NCT07048184 — Sarcoma Surgery Wound Complications Comparing Usual Versus Negative Pressure Dressing · Phase 2 · not yet recruiting
- NCT06786936 — Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06597045 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NHS Greater Glasgow and Clyde
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06597045.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing